A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). (Q38164670)

30 August 2017

A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). (English)

1 reference

30 August 2017

1 reference

1 reference

Alok Sharma

1

1 reference

PubMed ID

24259638

30 August 2017

Justin Couture

series ordinal

2

1 reference

PubMed ID

24259638

30 August 2017

language of work or name

English

0 references

publication date

1 November 2013

1 reference

Annals of Pharmacotherapy

30 August 2017

1 reference

30 August 2017

48

1 reference

30 August 2017

2

1 reference

30 August 2017

209-225

1 reference

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

30 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): What every clinician should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) improve memory of emotional stimuli in ADHD-diagnosed college students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

An analysis of rat prefrontal cortex in mediating executive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Dynamic Network Connectivity: A new form of neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

The neuropsychopharmacology of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

21 January 2018

Neurobiology of ADHD.

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Striatal Dopamine Transporter Alterations in ADHD: Pathophysiology or Adaptation to Psychostimulants? A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Candidate gene studies of ADHD: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Anomalous dopamine release associated with a human dopamine transporter coding variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Incoherence of neuroimaging studies of attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Neuroimaging of attention deficit hyperactivity disorder: can new imaging findings be integrated in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Spectroscopic findings in attention-deficit/hyperactivity disorder: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Converging methods in studying attention-deficit/hyperactivity disorder: what can we learn from neuroimaging and genetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Positron emission tomography neuroimaging for a better understanding of the biology of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Treatment of attention deficit hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

The influence of sex-linked genetic mechanisms on attention and impulsivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Treatment of attention-deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Recent developments in the psychosocial treatment of adult ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

3-Year Follow-up of the NIMH MTA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Attention-deficit-hyperactivity disorder: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Amphetamine: effects on catecholamine systems and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Carrier-mediated release of neurotransmitters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, mul

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Development of a rational scale to assess the harm of drugs of potential misuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Comorbidity of ADHD and Substance Use Disorder (SUD): a neuroimaging perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Adolescent suicidality in urban minorities and its relationship to conduct disorders, depression, and separation anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Growth on stimulant medication; clarifying the confusion: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Corpus callosum anatomy in chronically treated and stimulant naïve ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

ADHD drugs and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Treatment of attention deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Serum and brain concentrations of methylphenidate: implications for use and abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Nonstimulant treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Neurochemical modulation of response inhibition and probabilistic learning in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Non-stimulant medications in the treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Catecholamine modulators: lessons from nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Nonstimulant medications for the treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Effects of ?2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Steady-state pharmacokinetics of bupropion SR in juvenile patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013510699

21 January 2018

Identifiers

DOI

10.1177/1060028013510699

1 reference

30 August 2017

1 reference

PubMed ID

24259638